Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Treatment Considerations for Patients With HER2+ NSCLC
Panelists discuss how clinicians carefully weigh the efficacy of HER2-directed therapies against their safety profiles, particularly focusing on managing serious adverse events like interstitial lung disease, while also considering emerging strategies to combat resistance to these treatments as research in the field progresses.
EP: 1.Introduction and Current Landscape of HER2 in NSCLC
EP: 2.Safety and Efficacy of HER2-Directed ADCs for NSCLC
Now Viewing
EP: 3.Treatment Considerations for Patients With HER2+ NSCLC
EP: 4.Latest Advances and Therapies for HER2+ NSCLC
EP: 5.Unmet Needs and Clinical Considerations for HER2+ NSCLC
EP: 6.Integrating HER2-Directed Therapies Into Standard Care for NSCLC
EP: 7.HER2- Mutation Testing Considerations and Timing
EP: 8.Factors Impacting Use of HER2 Therapies for NSCLC
EP: 9.Incorporating Real-World Evidence for HER2+ NSCLC
EP: 10.Key Takeaways on the Future of HER2 in NSCLC
EP: 11.Real-World Outcomes in HER2-Positive NSCLC
EP: 12.Managing Treatment Challenges in HER2-Directed Therapies
EP: 13.Emerging Horizons in HER2-Directed NSCLC Treatments
EP: 14.Patient Selection and Personalized Treatment Strategies
EP: 15.Navigating Healthcare Access and Decision-Making
Video content above is prompted by the following:
- How do clinicians balance the efficacy and safety profiles of these therapies, particularly considering adverse events like interstitial lung disease?
- (Bazhenova) How might strategies to address resistance to HER2-directed therapies evolve with ongoing research?
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
